Anti-LAG-3 agents are under investigation in phase I–III trials in a wide array of solid tumors including lung, gastric, head and neck, hepatocellular and renal cancer as well as lymphoma and melanoma [11]. The gene discussed is LAG3; the disease is melanoma.